Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 11-20 of 30 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Extension Study to Evaluate NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep (Steamboat 2)

    Rochester, MN

  2. A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

    Jacksonville, FL

  3. Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

    Rochester, MN

  4. An Open-label Extension Trial of the Effectiveness and Safety of CVL-865 to Treat Focal Onset Seizures.

    Jacksonville, FL

  5. A Study Evaluating the Use of 48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer’s Disease

    Jacksonville, FL

  6. Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

    Rochester, MN

  7. Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

    Rochester, MN

  8. Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Subjects With SCN8A-DEE

    Rochester, MN

  9. A Study of Mood Symptoms in Epilepsy Patients

    Rochester, MN

  10. A Study to Evaluate Newly-diagnosed Idiopathic Generalized Epilepsy

    Rochester, MN

.

Mayo Clinic Footer